Skip to main content
. 2009 Dec 14;28(3):398–404. doi: 10.1200/JCO.2009.25.4920

Table 3.

Percent Kinase Target Inhibition of Dasatinib Over Time

Time on Dasatinib (months) No. of Evaluable Patients Detectable p-CrkL-Tyr207
Detectable pABL-Tyr245
No. of Patients % No. of Patients %
1 38 36 94.7 30 78.9
3 36 7 19.4 6 16.7
6 38 4 10.5 3 7.9
12 32 2 6.2 1 3.1
18 23 3 13.0 2 8.7